Directed new share issue in XVIVO Perfusion AB (SE) — SEK 500 million

Carnegie acted as sole global co-ordinator and sole bookrunner in the directed new share issues of 2,118,640 new shares at a subscription price of SEK 236 per share. XVIVO Perfusion is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation. September 2020.